Enterprise Value
491M
Cash
903.7M
Avg Qtr Burn
-38.97M
Short % of Float
15.20%
Insider Ownership
5.44%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis | Phase 3 Data readout | |
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis , Cirrhosis | Phase 3 Initiation | |
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis , Cirrhosis | Phase 2b Data readout | |
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis | Phase 2b Update |